menu
    • menu
    [{"orgOrder":0,"company":"Biocodex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Dermatology","graph2":"Phase IV","graph3":"Biocodex","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocodex \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Biocodex \/ Undisclosed"},{"orgOrder":0,"company":"Biocodex","sponsor":"Exystat","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Stiripentol","moa":"GABA(A) receptor gamma-3 (GABRG3)","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Biocodex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biocodex \/ Exystat","highestDevelopmentStatusID":"10","companyTruncated":"Biocodex \/ Exystat"},{"orgOrder":0,"company":"Biocodex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Stiripentol","moa":"GABA(A) receptor gamma-3 (GABRG3)","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Biocodex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biocodex \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocodex \/ Undisclosed"},{"orgOrder":0,"company":"Biocodex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Stiripentol","moa":"GABA(A) receptor gamma-3 (GABRG3)","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biocodex","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biocodex \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Biocodex \/ Undisclosed"},{"orgOrder":0,"company":"Biocodex","sponsor":"PANTHERx Rare Pharmacy","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Partnership","leadProduct":"Stiripentol","moa":"GABA(A) receptor gamma-3 (GABRG3)","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biocodex","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biocodex \/ PANTHERx Rare Pharmacy","highestDevelopmentStatusID":"15","companyTruncated":"Biocodex \/ PANTHERx Rare Pharmacy"},{"orgOrder":0,"company":"Biocodex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Stiripentol","moa":"GABA(A) receptor gamma-3 (GABRG3)","graph1":"Nephrology","graph2":"Phase I","graph3":"Biocodex","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocodex \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biocodex \/ Undisclosed"},{"orgOrder":0,"company":"Biocodex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Stiripentol","moa":"GABA(A) receptor gamma-3 (GABRG3)","graph1":"Neurology","graph2":"Phase IV","graph3":"Biocodex","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocodex \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Biocodex \/ Undisclosed"},{"orgOrder":0,"company":"Biocodex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Stiripentol","moa":"GABA(A) receptor gamma-3 (GABRG3)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Biocodex","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocodex \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biocodex \/ Undisclosed"},{"orgOrder":0,"company":"Biocodex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Stiripentol","moa":"GABA(A) receptor gamma-3 (GABRG3)","graph1":"Neurology","graph2":"Phase I","graph3":"Biocodex","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocodex \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biocodex \/ Undisclosed"},{"orgOrder":0,"company":"Biocodex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Etifoxine","moa":"GABA-A receptor; anion channel","graph1":"Undisclosed","graph2":"Phase III","graph3":"Biocodex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocodex \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocodex \/ Undisclosed"},{"orgOrder":0,"company":"Biocodex","sponsor":"MRM Health","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Probiotic","year":"2025","type":"Series B Financing","leadProduct":"MH002","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Biocodex","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0.059999999999999998,"dosageForm":"Capsule","sponsorNew":"Biocodex \/ Biocodex","highestDevelopmentStatusID":"9","companyTruncated":"Biocodex \/ Biocodex"},{"orgOrder":0,"company":"Biocodex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Probiotic","year":"2018","type":"Inapplicable","leadProduct":"Saccharomyces Boulardii","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Biocodex","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocodex \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Biocodex \/ Undisclosed"},{"orgOrder":0,"company":"Biocodex","sponsor":"Beth Israel Deaconess Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Probiotic","year":"2011","type":"Inapplicable","leadProduct":"Saccharomyces Boulardii","moa":"Immune","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Biocodex","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocodex \/ Biocodex","highestDevelopmentStatusID":"1","companyTruncated":"Biocodex \/ Biocodex"},{"orgOrder":0,"company":"Biocodex","sponsor":"Hilma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Biocodex","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder in Sachet","sponsorNew":"Biocodex \/ Biocodex","highestDevelopmentStatusID":"15","companyTruncated":"Biocodex \/ Biocodex"},{"orgOrder":0,"company":"Biocodex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Saccharomyces Boulardii","moa":"Immune","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Biocodex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biocodex \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocodex \/ Undisclosed"},{"orgOrder":0,"company":"Biocodex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Stiripentol","moa":"GABA(A) receptor gamma-3 (GABRG3)","graph1":"Neurology","graph2":"Approved FDF","graph3":"Biocodex","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biocodex \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Biocodex \/ Undisclosed"},{"orgOrder":0,"company":"Biocodex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Bacillus coagulans MY01","moa":"Microbiome","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Biocodex","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biocodex \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Biocodex \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Biocodex

    Menu

    Biocodex

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Biocodex

                            France arrow
                            OTS 2025
                            Not Confirmed

                            Biocodex

                            France arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bacillus coagulans MY01

                            Therapeutic Area : Gastroenterology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Probiotic and Ginger Supplement for Symptoms and Quality of Life in Functional Dyspepsia (SUBTILE)

                            Details : Bacillus coagulans MY01 is a Probiotic drug candidate, which is currently being evaluated in Undisclosed clinical studies for the treatment of Dyspepsia.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            October 08, 2025

                            Lead Product(s) : Bacillus coagulans MY01

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Biocodex

                            France arrow
                            OTS 2025
                            Not Confirmed

                            Biocodex

                            France arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Stiripentol

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioavailability of Stiripentol After Single Oral Dose of Capsule vs Suspension in Healthy Subjects (STILIQ)

                            Details : Stiripentol is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Epilepsies, Myoclonic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 16, 2025

                            Lead Product(s) : Stiripentol

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Biocodex

                            France arrow
                            OTS 2025
                            Not Confirmed

                            Biocodex

                            France arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Saccharomyces Boulardii

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome

                            Details : Saccharomyces Boulardii is a Probiotic drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Irritable Bowel Syndrome.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            September 11, 2025

                            Lead Product(s) : Saccharomyces Boulardii

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Biocodex

                            France arrow
                            OTS 2025
                            Not Confirmed

                            Biocodex

                            France arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MH002

                            Therapeutic Area : Immunology

                            Study Phase : Phase I/ Phase II

                            Recipient : MRM Health

                            Deal Size : $64.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            MRM Health Raises €55 Million Series B to Advance Best-in-Class Microbiome Pipeline

                            Details : The net proceeds will enable MRM Health to complete a Phase 2b clinical trial for its lead program MH002 in patients suffering from mild-to-moderate ulcerative colitis.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Undisclosed

                            September 04, 2025

                            Lead Product(s) : MH002

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : MRM Health

                            Deal Size : $64.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Biocodex

                            France arrow
                            OTS 2025
                            Not Confirmed

                            Biocodex

                            France arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Stiripentol

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Biocodex Develops DIACOMIT® Oral Suspension for Dravet Syndrome in Children

                            Details : Diacomit (stiripentol) a GABA-A receptor inhibitor oral suspension, a new formulation is being investigated to aid in the treatment of dravet syndrome in young children.

                            Product Name : Diacomit

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 14, 2024

                            Lead Product(s) : Stiripentol

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Biocodex

                            France arrow
                            OTS 2025
                            Not Confirmed

                            Biocodex

                            France arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Stiripentol

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase III

                            Sponsor : Exystat

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of the Efficacy and Safety of Stiripentol in Patients 6 Years and Older With Primary Hyperoxaluria ...

                            Details : Stiripentol is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hyperoxaluria, Primary.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 18, 2024

                            Lead Product(s) : Stiripentol

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase III

                            Sponsor : Exystat

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Biocodex

                            France arrow
                            OTS 2025
                            Not Confirmed

                            Biocodex

                            France arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amoxicillin Trihydrate

                            Therapeutic Area : Dermatology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Saccharomyces Boulardii CNCM I-745 on Gut Microbiota in Patients Undergoing Antibiotic Therapy (in t...

                            Details : Amoxicillin is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Erythema Chronicum Migrans.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            June 11, 2024

                            Lead Product(s) : Amoxicillin Trihydrate

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Biocodex

                            France arrow
                            OTS 2025
                            Not Confirmed

                            Biocodex

                            France arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Stiripentol

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetic Parameters of Stiripentol in Renal Impaired Patients and Matching Controls With Normal Renal F...

                            Details : Stiripentol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Renal Insufficiency, Chronic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 21, 2023

                            Lead Product(s) : Stiripentol

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Biocodex

                            France arrow
                            OTS 2025
                            Not Confirmed

                            Biocodex

                            France arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Recipient : Hilma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Biocodex Group Strengthens Its Position in the US Market With the Acquisition of Hilma, a Fast-Growing Natural...

                            Details : The acquisition is a key part of the Group’s international growth strategy and will enable Biocodex to consolidate its presence in the digestive health and women’s health segments of the US market.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            November 17, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Recipient : Hilma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Biocodex

                            France arrow
                            OTS 2025
                            Not Confirmed

                            Biocodex

                            France arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Stiripentol

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Antiseizure Drug DIACOMIT Now Approved for Children as Young as 6 Months

                            Details : DIACOMIT (stiripentol) is an effective treatment for seizures that are often resistant to other antiepileptic drugs. In two clinical studies, DIACOMIT reduced generalized clonic or tonic-clonic seizures by a median of 84% compared with 5.8% on placebo af...

                            Product Name : Diacomit

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 21, 2022

                            Lead Product(s) : Stiripentol

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth